Treatment with angiotensin II receptor blockers is associated with prolonged relapse-free survival, lower relapse rate, and corticosteroid-sparing effect in patients with giant cell arteritis

Seminars in Arthritis and Rheumatism

Volumn 43, Issue 6, 2014, Pages 772-777

  Alba, Marco A ^a   García Martínez, Ana ^a   Prieto González, Sergio ^a   Espígol Frigolé, Georgina ^a   Butjosa, Montserrat ^a   Tavera Bahillo, Itziar ^a   Rodríguez Pintó, Ignasi ^a   Hernández Rodríguez, José ^a   Cid, Maria C ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Angiotensin receptors blockers; Angiotensin converting enzyme inhibitors; Giant cell arteritis; Relapses; Treatment

Indexed keywords

ALKALINE PHOSPHATASE; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HAPTOGLOBIN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; GLUCOCORTICOID;

AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GIANT CELL ARTERITIS; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; THROMBOCYTE COUNT; TREATMENT DURATION; VERY ELDERLY; VISUAL IMPAIRMENT; DISEASE FREE SURVIVAL; DRUG COMBINATION; LONGITUDINAL STUDY; PROPORTIONAL HAZARDS MODEL; RECURRENT DISEASE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; GIANT CELL ARTERITIS; GLUCOCORTICOIDS; HUMANS; LONGITUDINAL STUDIES; MALE; PREDNISONE; PROPORTIONAL HAZARDS MODELS; RECURRENCE; TREATMENT OUTCOME;

EID: 84902500045     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2013.10.009     Document Type: Article

References (57)

1. Jennette J.C., Falk R.J., Bacon P.A., Basu N., Cid M.C., Ferrario F., et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum 2013, 65:1-11.
2. Salvarani C., Pipitone N., Versari A., Hunder G.G. Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat Rev Rheumatol 2012, 8:509-521.
3. Bongartz T., Matteson E.L. Large-vessel involvement in giant cell arteritis. Curr Opin Rheumatol 2006, 18:10-17.
4. Cid M.C., García-Martínez A., Lozano E., Espígol-Frigolé G., Hernández-Rodríguez J. Five clinical conundrums in the management of giant cell arteritis. Rheum Dis Clin North Am 2007, 33:819-834.
5. Alba M.A., García-Martínez A., Tavera-Bahillo I., Prieto-González S., Butjosa M., Espígol G., et al. Relapses in patients with giant-cell arteritis: prevalence, characteristics and associated clinical findings in a prospectively followed cohort of 106 patients. Arthritis Rheum 2012, 64:S994. [abstract 2357].
6. Wilke W.S., Hoffman G.S. Treatment of corticosteroid-resistant giant cell arteritis. Rheum Dis Clin North Am 1995, 21:59-71.
7. Martínez-Lado L., Calvino-Díaz C., Pineiro A., Dierssen T., Vázquez-Rodríguez T.R., Miranda-Filloy J.A., et al. Relapses and recurrences in giant cell arteritis: a population-based study of patients with biopsy-proven disease from northwestern Spain. Medicine 2011, 90:186-193.
8. Andersson R., Malmvall B.E., Bengtsson B.A. Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scand 1986, 220:465-469.
9. Proven A., Gabriel S.E., Orces C., O'Fallon W.M., Hunder G.G. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003, 49:703-708.
10. Nesher G., Sonnenblick M., Friedlander Y. Analysis of steroid related complications and mortality in temporal arteritis: a 15-year survey of 43 patients. J Rheumatol 1994, 21:1283-1286.
11. García-Martínez A., Hernández-Rodríguez J., Arguis P., Paredes P., Segarra M., Lozano E., et al. Development of aortic aneurysm/dilatation during the follow up of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. Arthritis Rheum 2008, 59:422-430.
12. Hoffman G.S., Cid M.C., Hellmann D.B., Guillevin L., Stone J.H., Schousboe J., et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002, 46:1309-1318.
13. Jover J.A., Hernández-García C., Morado I.C., Vargas E., Banares A., Fernández-Gutiérrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001, 134:106-114.
14. Spiera R.F., Mitnick H.J., Kupersmith M., Richmond M., Spiera H., Peterson M.G., et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 2001, 19:495-501.
15. Mahr A.D., Jover J.A., Spiera R.F., Hernández-García C., Fernández-Gutiérrez B., Lavalley M.P., et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007, 56:2789-2797.
16. De Silva M., Hazleman B.L. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986, 45(2):136-138.
17. Hoffman G.S., Cid M.C., Rendt-Zagar K.E., Merkel P.A., Weyand C.M., Stone J.H., et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007, 146(9):621-630.
18. Martinez-Taboada V.M., Rodriguez-Valverde V., Carreno L., Lopez-Longo J., Figueroa M., Belzunegui J., et al. A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. Ann Rheum Dis 2008, 67(5):625-630.
19. Loock J., Henes J., Kotter I., Witte T., Lamprecht P., Schirmer M., et al. Treatment of refractory giant cell arteritis with cyclophosphamide: a retrospective analysis of 35 patients from three centres. Clin Exp Rheumatol 2012, 30:S70-S76.
20. Unizony S.H., Dasgupta B., Fisheleva E., Rowell L., Schett G., Spiera R., et al. Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol 2013, 2013:10.
21. Touyz R.M. Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II. Curr Opin Nephrol Hypertens 2005, 14:125-131.
22. Martin M.F., Surrall K.E., McKenna F., Dixon J.S., Bird H.A., Wright V. Captopril: a new treatment for rheumatoid arthritis?. Lancet 1984, 1325-1328.
23. Flammer A.J., Sudano I., Hermann F., Gay S., Forster A., Neidhart M., et al. Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation 2008, 117(17):2262-2269.
24. Duran-Barragan S., McGwin G., Vila L.M., Reveille J.D., Alarcon G.S. Angiotensin-converting enzyme inhibitors delay the occurrence of renal involvement and are associated with a decreased risk of disease activity in patients with systemic lupus erythematosus-results from LUMINA (LIX): a multiethnic US cohort. Rheumatology (Oxford) 2008, 47:1093-1096.
25. Crowley S.D., Vasievich M.P., Ruiz P., Gould S.K., Parsons K.K., Pazmino A.K., et al. Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis. J Clin Invest 2009, 119:943-953.
26. Stegbauer J., Lee D.H., Seubert S., Ellrichmann G., Manzel A., Kvakan H., et al. Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proc Natl Acad Sci U S A 2009, 106:14942-14947.
27. Meroni P.L., Luzzana C., Ventura D. Anti-inflammatory and immunomodulating properties of statins. An additional tool for the therapeutic approach of systemic autoimmune diseases?. Clin Rev Allergy Immunol 2002, 23:263-277.
28. Fernandes J.L., de Oliveira R.T., Mamoni R.L., Coelho O.R., Nicolau J.C., Blotta M.H., et al. Pentoxifylline reduces pro-inflammatory and increases anti-inflammatory activity in patients with coronary artery disease-a randomized placebo-controlled study. Atherosclerosis 2008, 196:434-442.
29. Ruíz-Irastorza G., Ramos-Casals M., Brito-Zeron P., Khamashta M.A. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010, 69:20-28.
30. Mancini G.B., Henry G.C., Macaya C., O'Neill B.J., Pucillo A.L., Carere R.G., et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) study. Circulation 1996, 94:258-265.
31. Tikiz C., Utuk O., Pirildar T., Bayturan O., Bayindir P., Taneli F., et al. Effects of angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. J Rheumatol 2005, 32:2095-2101.
32. Funakoshi Y., Ichiki T., Shimokawa H., Egashira K., Takeda K., Kaibuchi K., et al. Rho-kinase mediates angiotensin II-induced monocyte chemoattractant protein-1 expression in rat vascular smooth muscle cells. Hypertension 2001, 38:100-104.
33. Ito T., Ikeda U., Yamamoto K., Shimada K. Regulation of interleukin-8 expression by HMG-CoA reductase inhibitors in human vascular smooth muscle cells. Atherosclerosis 2002, 165:51-55.
34. Kranzhofer R, Schmidt J, CA Pfeiffer, Hagl S, Libby P, Kubler W. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999;19:1623-9.
35. Costanzo A., Moretti F., Burgio V.L., Bravi C., Guido F., Levrero M., et al. Endothelial activation by angiotensin II through NFkappaB and p38 pathways: involvement of NFkappaB-inducible kinase (NIK), free oxygen radicals, and selective inhibition by aspirin. J Cell Physiol 2003, 195:402-410.
36. Piqueras L., Kubes P., Alvarez A., O'Connor E., Issekutz A.C., Esplugues J.V., et al. Angiotensin II induces leukocyte-endothelial cell interactions in vivo via AT(1) and AT(2) receptor-mediated P-selectin upregulation. Circulation 2000, 102:2118-2123.
37. Hernández-Rodríguez J., Segarra M., Vilardell C., Sánchez M., García-Martínez A., Esteban M.J., et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 2004, 43:294-301.
38. Cid M.C., Cebrian M., Font C., Coll-Vinent B., Hernández-Rodríguez J., Esparza J., et al. Cell adhesion molecules in the development of inflammatory infiltrates in giant cell arteritis: inflammation-induced angiogenesis as the preferential site of leukocyte-endothelial cell interactions. Arthritis Rheum 2000, 43:184-194.
39. Visvanathan S., Rahman M.U., Hoffman G.S., Xu S., García-Martínez A., Segarra M., et al. Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis-a prospective longitudinal study. Rheumatology (Oxford) 2011, 50:2061-2070.
40. Coll-Vinent B., Vilardell C., Font C., Oristrell J., Hernández-Rodríguez J., Yague J., et al. Circulating soluble adhesion molecules in patients with giant cell arteritis. Correlation between soluble intercellular adhesion molecule-1 (sICAM-1) concentrations and disease activity. Ann Rheum Dis 1999, 58:189-192.
41. García-Martínez A., Hernández-Rodríguez J., Espigol-Frigole G., Prieto-González S., Butjosa M., Segarra M., et al. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor alpha and interleukin-6) in the long-term followup of patients with giant cell arteritis. Arthritis Care Res 2010, 62:835-841.
42. Griendling K.K., Sorescu D., Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000, 86:494-501.
43. Ruperez M., Lorenzo O., Blanco-Colio L.M., Esteban V., Egido J., Ruíz-Ortega M. Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation 2003, 108:1499-1505.
44. Tunon J., Ruíz-Ortega M., Egido J. Regulation of matrix proteins and impact on vascular structure. Curr Hypertens Rep 2000, 2:106-113.
45. Ruíz-Ortega M., Lorenzo O., Suzuki Y., Ruperez M., Egido J. Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 2001, 10:321-329.
46. Lovrecic L., Ristic S., Starcevic-Cizmarevic N., Jazbec S.S., Sepcic J., Kapovic M., et al. Angiotensin-converting enzyme I/D gene polymorphism and risk of multiple sclerosis. Acta Neurol Scand 2006, 114:374-377.
47. Lee Y.H., Choi S.J., Ji J.D., Song G.G. Associations between the angiotensin-converting enzyme insertion/deletion polymorphism and susceptibility to vasculitis: a meta-analysis. J Renin Angiotensin Aldosterone Syst 2012, 13(1):196-201.
48. Ozkaya O., Soylemezoglu O., Gonen S., Misirlioglu M., Tuncer S., Kalman S., et al. Renin-angiotensin system gene polymorphisms: association with susceptibility to Henoch-Schonlein purpura and renal involvement. Clin Rheumatol 2006, 25:861-865.
49. Ozturk M.A., Calguneri M., Kiraz S., Ertenli I., Onat A.M., Ureten K., et al. Angiotensin-converting enzyme gene polymorphism in Behcet's disease. Clin Rheumatol 2004, 23:142-146.
50. Dimitrijevic I., Malmsjo M., Andersson C., Rissler P., Edvinsson L. Increased angiotensin II type 1 receptor expression in temporal arteries from patients with giant cell arteritis. Ophthalmology 2009, 116:990-996.
51. Guzik T.J., Hoch N.E., Brown K.A., McCann L.A., Rahman A., Dikalov S., et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007, 204:2449-2460.
52. Mazzolai L., Duchosal M.A., Korber M., Bouzourene K., Aubert J.F., Hao H., et al. Endogenous angiotensin II induces atherosclerotic plaque vulnerability and elicits a Th1 response in ApoE -/- mice. Hypertension 2004, 44:277-282.
53. Platten M., Youssef S., Hur E.M., Ho P.P., Han M.H., Lanz T.V., et al. Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc Natl Acad Sci U S A 2009, 106:14948-14953.
54. Lozano E., Segarra M., García-Martínez A., Espigol-Frigole G., Hernández-Rodríguez J., Cid M.C. New therapeutic targets in giant-cell arteritis. Considerations based on the current pathogenic model and the availability of new therapeutic agents. Clin Exp Rheumatol 2008, 26:S141-S150.
55. Espígol-Frigolé G., Corbera-Bellalta M., Planas-Rigol E., Lozano E., Segarra M., García-Martínez A., et al. Increased IL-17 A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis. Ann Rheum Dis 2013, 72:1481-1487.
56. González-Gay M.A., Pineiro A., Gómez-Gigirey A., García-Porrua C., Pego-Reigosa R., Dierssen-Sotos T., et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine 2004, 83:342-347.
57. Huang X.R., Chen W.Y., Truong L.D., Lan H.Y. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 2003, 14(7):1738-1747.